LivaNova PLC (LIVN)

55,75 -0,42 (-0,75%) Alla chiusura: 04:00PM EDT

LivaNova PLC

20 Eastbourne Terrace
London W2 6LG
United Kingdom
44 20 3325 0660
https://www.livanova.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 2.900

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Alex Shvartsburg	Chief Financial Officer	1,2M	N/D	1971
Deanna Wilke	Vice President of Corporate Communications	N/D	N/D	N/D
Mr. Matthew Joseph Dodds III	Senior Vice President of Corporate Development & IT	N/D	N/D	N/D
Dr. Bryan D. Olin Ph.D.	Senior VP & Head of Product Development - Neuromodulation	N/D	N/D	1967
Mr. Ryan Miller	President of Advanced Circulatory Support	N/D	N/D	N/D
Ms. Stephanie Bolton	President of Global Epilepsy	N/D	N/D	1982
Mr. John Webb	Vice President of Sleep Apnea and Epilepsy	N/D	N/D	N/D
Mr. Jonathan Walker	VP for Difficult-to-Treat Depression Segment	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di LivaNova PLC al 29 aprile 2024 è 3. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.